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NDRG2 is a member of the N-myc downstream regulated gene (NDRG) family, implicated in cell
growth and differentiation. Investigation of NDRG2 molecular interactions by yeast two-hybrid
screening identiﬁed prenylated Rab acceptor-1 (PRA1), involved in vesicle trafﬁcking and protein
transport, as binding partner. Binding of NDRG2 (and NDRG1-4) with PRA1 in vitro was conﬁrmed
by GST pull-down assay and immunoprecipitation, and colocalization was veriﬁed by confocal
microscopy in HCT116 cells. Intracellular coexpression showed that NDRG2 and PRA1 synergistically
downregulate T-cell factor (TCF) promoter activity and GSK3b phosphorylation. Results suggest that
NDRG2 and PRA1 might act synergistically to prevent signaling of TCF/b-catenin.
Structured summary of protein interactions:
NDRG2a binds to PRA1 by pull down (View interaction)
NDRG2a physically interacts with PRA1 by two hybrid (View Interaction: 1, 2)
PRA1 physically interacts with NDRG2a by anti tag coimmunoprecipitation (View interaction)
NDRG2a, PRA1 and Catenin beta colocalize by cosedimentation (View interaction)
NDRG2a and PRA1 colocalize by ﬂuorescence microscopy (View Interaction: 1, 2, 3)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction enzymatic catalytic motif [2]. There is divergence in the N- and C-The N-myc downstream regulated gene (NDRG) family consists
of four members, NDRG1–4 [1], which share 53–65% amino acid
identity. These proteins have been implicated in the regulation of
cell differentiation and proliferation, but they show distinct
patterns of tissue-, differentiation-, and developmental stage-asso-
ciated expression [1]. They are characterized by NDR- and a/b-
hydrolase-fold domains, although none of them has the expectedchemical Societies. Published by E
asmic reticulum; GFP, green
A, hemagglutinin; NDRG, N-
Rab acceptor-1; TCF, T-cell
mics Research Center, Korea
Yuseong, Daejeon 305-333,
); Department of Biological
eases, Sookmyung Women’s
2 2 2077 7322 (J.-S. Lim).
im), hglee@kribb.re.kr (H.G.termini, except for a conserved C-terminal ﬁve-amino acid motif
[1]. Unique functions of these proteins are thought to be due to three
GTRSRSHTSE tandem repeats in the C-terminal region ofNDRG1and
four consecutive Thr residues in the C-terminal hydrolase region of
NDRG4. The NDRG genes are located on different chromosomes and
are transcribed into multiple isoforms from distinct mRNAs [3].
Signiﬁcant attention has been paid to NDRG proteins due to
their potential as tumor suppressors and involvement in several
diseases [4]. The most extensively studied as a metastatic suppres-
sor is NDRG1 [1,5], and this family member has also been associ-
ated with cell growth regulation [6] and nerve myelination [7].
The NDRG1 protein is highly related to NDRG2, and downregula-
tion of the latter has been reported in several human cancers and
cell lines, including those of pancreas, breast, meningioma, and
glioblastoma [8–10]. Few data exist regarding NDRG3 and NDRG4
in cancers [1], although NDRG3 has been seen to be
overexpressed in prostate cancer [11] and NDRG4 in glioblastoma
[12]. Melotte et al. [13] have proposed NDRG4 as a candidate tu-
mor suppressor gene in colorectal cancer (CRC), where its expres-lsevier B.V. All rights reserved.
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Fig. 1. Binding domain mapping of NDRG2 and PRA1. (A) Schematic representation
of various mutations of NDRG2 and PRA1. NDRG2 contains a a/b-hydrolase domain,
and PRA1 has two transmembrane domains. TM, transmembrane; T, threonine; S,
serine; AA, amino acids. (B) Yeast two-hybrid binding assay of NDRG2 and PRA1.
pLexA- and pB42AD-constructs plasmids as indicated were cotransformed, and
protein–protein binding was assessed by b-galactosidase activity. Strong protein–
protein interaction in yeast clones is indicated by blue colonies on the indicator
plates used.
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Fig. 2. Downregulation of NDRG2 and PRA1 in colorectal cancer tissues. (A) Tissue
lysates from tumor and adjacent normal mucosal tissue were subjected by Western
blot analysis, with a-tubulin as internal control. The histogram shows relative band
intensities in arbitrary densitometric units. N, normal; T, tumor. (B) After HCT116
cells were transfected with pcDNA3.1–NDRG2a (b) or pEGFP–NDRG2a (b),
Western blot and confocal microscopy were conducted.
J.-T. Kim et al. / FEBS Letters 586 (2012) 3962–3968 3963sion is inactivated by promoter methylation. Lusis et al. [8] ob-
served that the NDRG2 promoter was hypermethylated during
meningioma progression, and this has also been observed in glio-
blastoma [12]. Indeed, accumulating evidence suggests that
NDRG2 plays a role as a tumor suppressor, but the exact molecular
function remains elusive.
We have sought to gain understanding of the precise molecular
and cellular functions of NDRG2 by identifying proteins with which
it physically interacts. By yeast two-hybrid screening, prenylated
Rab acceptor 1 (PRA1/RABAC1) was identiﬁed as a binding partner.
In this study, we show that NDRG2 colocalizes with PRA1 in the
cytosol near the outer surface of the nucleus, and this interaction
is associated with synergistic inhibition of T-cell factor (TCF)/b-
catenin signaling through blocking the phosphorylation of GSK3b.
2. Materials and methods
2.1. Cell culture and tumor tissues
Colorectal cancer HCT116 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Gibco-BRL, Grand Island, NY)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(Gibco-BRL), 1% (w/v) penicillin/streptomycin. Tumor and adjacent
normal mucosal tissues were obtained from patients with CRC. All
subjects were advised of the procedures and provided written
informed consent. The studies were approved by the ethics
committee of the Samsung Medical Center (Seoul, South Korea).
2.2. Yeast two-hybrid screening and b-galactosidase reporter assay
A full-length cDNA containing the coding region of NDRG2awas
subcloned into the pLexA vector (Clontech, Palo Alto, CA) to
generate a LexA–NDRG2a fusion construct. The pLexA–NDRG2a-
containing plasmid was then transformed into yeast Saccharomyces
cerevisiae strain EGY48. For library screening, the LexA–NDRG2a-
containing yeast cells were transfected with a human fetal brain
cDNA library (10 lg) according to the protocol recommended in
the Matchmaker Two-Hybrid System (Clontech). After the NDRG2a
interactions were conﬁrmed via yeast two-hybrid assay, positive
cDNA clones were sequenced and identiﬁed by BLAST analysis.
For b-galactosidase reporter assays, NDRG2a wild-type and mutant
sequences were cloned into the pLexA vector, and PRA1 wild-type
and mutant sequences into the pB42AD vector. After cotransfec-
tion, yeast cells were lysed and measured b-galactosidase activity
according to the Clontech Matchmaker manual.
2.3. Wild-type and mutant NDRG2 and PRA1 clones
Sequences containing the coding region of human NDRG2a
(GenBank accession number NM_201540, isoform a) and NDRG2b
(NM_016250, isoform b) were ampliﬁed by PCR from dendritic cell
cDNA [14]. The following NDRG2a deletion or point mutations
were generated: NDRG2N, amino acids (AA) 1–164; NDRG2C,
AA165–371; NDRG2H, AA99–371; NDRG2TA, mutation of Thr330
to Ala (Thr330Ala); NDRG2SA, Ser332Ala; NDRG2TSAA, Thr330Ala
and Ser332Ala. Sequences containing the PRA1 coding region were
ampliﬁed by PCR from a Jurkat cell cDNA library [15], and the
following mutations were generated: PRA1N1, AA1–61; PRA1N2,
AA1–78; PRA1N3, AA30–100; PRA1TM, AA62–185; PRA1TM1,
AA79–138; PRA1TM2, AA139–185; PRA1D185, deletion of Val185;
PRA1DTM, deletion of AA65164.
2.4. In vitro translation assay
The GST or GST-NDRG2a proteins synthesized in Escherichia
coli BL21 were immobilized on glutathione-sepharose 4B beads
3964 J.-T. Kim et al. / FEBS Letters 586 (2012) 3962–3968(Amersham Pharmacia, Piscataway, NJ). For 35S-Met labeling of
PRA1, the T7 TNT transcription–translation system (Promega, Mad-
ison, WI) was used and pulled down GST. After centrifugation, pro-
teins attached to the beads were eluted in SDS-containing sample
buffer, boiled and then subjected to separation by SDS–PAGE in
15% (w/v) polyacrylamide gels, followed by autoradiography.
2.5. Transfection, Western blots, and immunoprecipitation
One day before transfection, HCT116 cells were plated in multi-
well dishes at 70–80% conﬂuence. Transfection was performed
using the Invitrogen Lipofectamine 2000 reagent (Invtirogen,
Carlsbad, CA) according to the manufacturer’s instructions. For
Western blot analysis and immunoprecipitation, cell extracts were
prepared as previously described [15].
2.6. Laser scanning confocal microscopy
Transfected HCT116 cells were ﬁxed as described previously
[15]. Laser scanning confocal microscopy (LSM510Meta; Carl Zeiss,
Jena, Germany) was performed and images captured by Zeiss LSM
Image Browser program.
2.7. Cell proliferation and luciferase reporter assay
1  104 cells/well in a 96-well plate were transfected with
pcDNA3.1-constructs and cell proliferation rates were determined
using WST1 Cell Proliferation reagent (Boehringer Mannheim,A
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Fig. 3. NDRG2 interacts with PRA1. (A) In vitro GST pull-down assay of NDRG2a and
glutathione–sepharose resin, 35S-PRA1 was added and GST pull-down conducted. Bound
assessed by immunoprecipitation in HCT116. After transfection, lysates were immuno
immunoglobulin heavy chain; IgL, immunoglobulin light chain; WCL, whole cell lysate
HCT116. Cotransfections were as follows: a, pEGFP + pcDNA3–NDRG2a; b, pEGFP + pcDN
PRA1; e, pEGFP–NDRG2a + pcDNA3–PRA1DVal; f, pEGFP–PRA1 + pcDNA3–NDRG2b; g, pMannheim, Germany). Cells were incubated with 10 ll of the
WST1 reagent at 37 C for 1 h in a 5% CO2 incubator, and the absor-
bance at 450 nmwas measured using a microplate reader (Molecu-
lar Devices, CA). For luciferase assays, cells in 6-well plates were
transfectedwith pTOPﬂash-wt (or pFOPﬂash-mut) luciferase repor-
ter (Upstate Biotechnology), b-galactosidase (for normalization),
pcDNA3–NDRG2a and/or -PRA1 plasmid DNA. After 48 h, cells were
lysed in lysis buffer (Promega, Madison WI) and monitored with a
plate-reading luminometer (Bio–Rad Laboratories, Hercules, CA).
2.8. Statistical analysis
Data are presented as mean values ± S.D. from three
independent experiments performed in triplicate, and statistical
signiﬁcance was assessed by two-tailed unpaired Student’s t test.
P-values of < 0.05 were considered signiﬁcant.
3. Results
3.1. Protein interaction between the a/b-hydrolase domain of NDRG2
and the C-terminal transmembrane domain of PRA1
By yeast two-hybrid screening, we found PRA1 to be a binding
partner for NDRG2 (data not shown). The speciﬁc binding domains
important for the interaction were examined in selected subclones
and mutations in recombinant pLexA and pB42AD fusion plasmids
(Fig. 1A), cotransformed into yeast EGY48 to measure protein–
protein interaction that activates LacZ reporter expression. AsMergedGFP-fused TRITC
PRA1. After control GST or GST–NDRG2a fusion proteins were immobilized on
complexes were analyzed by autoradiography. (B) Interaction of NDRG2a and PRA1
precipitated with anti-HA antibody, and subjected to Western blot analysis. IgH,
s. (C) Immunoﬂuorescence colocalization analysis of cellular NDRG2 and PRA1 in
A3HA–PRA1; c, pEGFP–NDRG2a + pcDNA3HA–PRA1; d, pEGFP–NDRG2a + pcDNA3–
EGFP–PRA1DTM + pcDNA3–NDRG2a.
J.-T. Kim et al. / FEBS Letters 586 (2012) 3962–3968 3965shown in Fig. 1B, NDRG2a exhibited strong binding to PRA1,
whereas NDRG2H and NDRG2C weakly bound, and NDRG2N was
not interactive. The transmembrane-containing C-terminal region
of PRA1 was necessary for binding to NDRG2a, and mutation in
C-terminal Val185 of PRA1 was not affected to the interaction of
NDRG2–PRA1. It is known that the C-terminal Val185 residue of
PRA1 is essential for dimerization and endoplasmic reticular (ER)
export [17]. On the other hand, N-terminal transmembrane-de-
leted (PRA1N1, -N2) and selected deletion mutants (PRA1TM1, -
TM2, -N3) of PRA1 showed weak or no interaction with NDRG2a,
suggesting that PRA1 protein structure is important for binding.
The interaction of LexA–PRA1 or B42–PRA1 resulted in strong
b-galactosidase activity, as did LexA–NDRG2a or B42–NDRG2b.
3.2. Downregulation of NDRG2 and PRA1 in colorectal cancer tissues
Recently, we found that NDRG2 was highly downregulated at
mRNA and protein levels in colorectal cancer (CRC) tissues [26],
in accordance with that NDRG2 has been shown to be downregu-
lated in several cancers including prostate and breast cancers
[9,16]. Levels of NDRG2 protein were found to be approximatelyA
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Fig. 4. Synergistic inhibition of TCF/b-catenin signaling by NDRG2–PRA1 interaction. (
cotransfected with pcDNA3–NDRG2a, pTOPﬂash- (or pNF-jB- or pAP1-) luciferase, and b-
to units of b-galactosidase. Mean ± S.D. values from three independent experiments pe
inhibition of TCF activity by NDRG2a–PRA1. Cells were cotransfected with plasmids, an
versus TCF/NDRG2a. T, Thr330Ala; S, Ser332Ala; TS, Thr330Ala and Ser332Ala; b, NDRG2b
cotransfected with pcDNA3–NDRG2a and/or pcDNA3–PRA1 were treated with LiCl
translocation by NDRG2a. Transfected cells with either pEGFP or pEGFP–NDRG2a or LiC
laser microscopy. Arrows indicate nuclear b-catenin. (E) Nuclear and cytosolic fractions
Nuclear b-catenin band intensity (-fold) relative to that of PARP. (F) GSK3b phosphorylat
pcDNA3–PRA1 were lysed and proteins subjected to Western blot analysis. (G) Cells were
relative to that of total GSK3b.2.5-fold lower in CRC versus normal adjacent mucosa (Fig. 2A)
and approximately 3.4-fold lower for levels of PRA1.
3.3. Expression of protein from transfected constructs
For controlled NDRG2 expression in cells, NDRG2a cDNA from
dendritic cells [14] was subcloned into mammalian expression
vectors pEGFP and pcDNA3.1. NDRG2 has two alternative protein
isoforms: 371-amino acids of NDRG2a and 357-amino acids of
NDRG2b (N-terminal 14 amino acids deleted). As shown in
Fig. 2B, both proteins were well expressed from transfected recom-
binant clones. The sizes of the two proteins were correct, and the
cellular distribution was similar (cytoplasmic localization near
the outer nuclear surface, and weakly in the nucleus).
3.4. NDRG2 interacts with PRA1 in vitro and in vivo
To conﬁrm NDRG2-PRA1 binding, in vitro GST pull-down assay
was conducted using fusion GST–NDRG2 and 35S-Met–PRA1
proteins. As shown in Fig. 3A 35S-PRA1 speciﬁcally binds
GST–NDRG2a. Results of immunoprecipitation assays with HA fu-F
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3966 J.-T. Kim et al. / FEBS Letters 586 (2012) 3962–3968sion proteins (Fig. 3B) indicate that NDRG2a binds directly or indi-
rectly to PRA1 intracellularly. Confocal microscopy in HCT116 cells
shows a colocalized distribution of NDRG2 and PRA1 proteins in
the cytoplasm near the outer surface of the nucleus (Fig. 3C-c, -d,
and -f). In cells cotransfected with GFP–NDRG2a and PRA1–DVal
(Fig. 3C-e), colocalization is observed; however, this is not the case
with transmembrane-deleted PRA1DTM (Fig. 3C-g), suggesting
that NDRG2may colocalize in the ER and Golgi complex with PRA1.
3.5. NDRG2-PRA1 synergistically inhibits TCF signaling by blocking
phosphorylation of GSK3b
Previously, we reported that PRA1 inhibits TCF signaling via b-
catenin binding [15]. When HCT116 cells are cotransfected with
NDRG2a and transcriptional reporter plasmids (Fig. 4A), TCF pro-
moter activity is reduced by 50% in NDRG2a-overexpressing cells
compared to control cells. In contrast, NF-jB and AP1 promoter
activities are not affected in these conditions. Cotransfection of
NDRG2a (or NDRG2b) and PRA1, versus individual transfection
alone, reveals synergistic inhibition of TCF promoter activity
(Fig. 4B). Thr330, Ser332, and Thr348 residues of NDRG2a, known
to be phosphorylated by SGK1, PKC, and AKT [18], are not involved
in this effect. Inhibition of GSK3b by LiCl upregulates TCF promoter,
and this effect is antagonized by coexpression of PRA1 and NDRG2a
(Fig. 4C).A
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To identify which molecules are affected in the TCF/b-catenin sig-
naling in NDRG2a–PRA1-overexpressing cells, Western blot analy-
sis was conducted. As shown in Fig. 4F, the phosphorylation of AKT
and GSK3b activity is decreased, and cyclin D1 levels, as expected,
are signiﬁcantly lower. Additionally, when cells were cotransefcted
with NDRG2a and PRA1 followed by LiCl treatment (Fig. 4G), the
phosphorylation of GSK3b was obviously blocked in NDRG2 and
PRA1 overexpressed cells. This suggests that NDRG2 and PRA1
may contribute to inhibition of GSK3b phosphorylation, which in
turn is involved in TCF/b-catenin signaling.
3.6. NDRG proteins interact with PRA1 and downregulate cell
proliferation
To understand the extent of interaction between NDRG proteins
and PRA1, NDRG1 (394 AA), NDRG3 (375 AA), and NDRG4 (385 AA)
clones were analyzed by Western blot and confocal microscopy in
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PRA1 distribution. Immunoprecipitation of GFP fusion proteins
with anti-GFP antibody resulted in coprecipitation of PRA1
(Fig. 5B). It is likely that the NDRG a/b-hydrolase motif is involved
in PRA1 binding, because differences between NDRG proteins are
predominantly located in the N- and C-terminal regions. As with
NDRG2, NDRG1- or NDRG3-overexpressing cells show decreased
cellular growth (Fig. 5C) and downregulated TCF promoter activity
(Fig. 5D), and those effects result from synergy with PRA1. Mean-
while, NDRG4-overexpressing cells showed a slightly increased
cellular growth and TCF promoter activation (Fig. 5C and D).
PRA1 interacted with NDRG4 (Fig. 5B) and thereby NDRG4-
mediated cell growth and TCF activation were signiﬁcantly
blocked.
4. Discussion
The identiﬁcation of PRA1 as interaction partner with NDRG
proteins, and cellular effects we have found, is important for
understanding the function of these proteins. Our reporter assay
and immunoprecipitation results with deletion mutants suggest
that the NDRG a/b-hydrolase domain is likely to be involved in
PRA1 association. While evidence supporting direct binding of
NDRG2 and PRA1 was presented, further studies are required for
direct versus indirect binding of the other NDRG proteins. The cel-
lular distribution of PRA1 in the ER and Golgi complex has been ob-
served by several laboratories [19,20]. The C-terminus of PRA1 is
required for the Golgi localization and for binding of Rab GTPases,
and its C-terminal Val185 residue and the di-acidic DXEE motif are
required for export from the ER to the Golgi complex and homodi-
mer formation [17,21]. Previously, we reported [15] that the trans-
membrane domain of PRA1 was important for the inhibition of
TCF/b -catenin signaling, but the C-terminal Val185 was not. We
found here that NDRG2 colocalization is independent of the PRA1
Val185 residue.
NDRG1 andNDRG2 contain several potential SGK1, PKC, and AKT
phosphorylation sites, conﬁrmed in certain cell types [18]. This sug-
gests that NDRG2 may be broadly involved in stress responses, cell
proliferation, and differentiation. Signaling of TCF/b -catenin has
been implicated in regulation of colonic epithelial cell proliferation
and differentiation [22]. The cytosolic concentration of b-catenin is
regulated by antigen-presenting cell tumor suppressor and phos-
phorylation at its N-terminus by the interaction with GSK3b [23].
Non-phosphorylated cytosolic b-catenin eventually results in the
formation of the TCF/b-catenin complex and its nuclear transloca-
tion, followed by tumor formation via upregulation of
c-Myc and cyclin D1 [24,25]. We observed here that TCF promoter
activity is inhibited by NDRG2 overexpression, and the activity is
synergistically downregulated by cotransfection with PRA1. Fur-
thermore, GSK3b phosphorylation is signiﬁcantly blocked by
NDRG2 and PRA1. Although the exact mechanism of the inhibition
of GSK3b phosphorylation by NDRG2 and PAR1 is not known, the
synergistic effectmay be of importance. It was reported that NDRG2
modulates intracellular signals controlling cell cycle via c-Jun phos-
phorylation, followed by downregulation of AP1 and cyclin D1 [24],
and thatNDRG2 reduces the transcriptional activity of TCF in SW620
cells [26]. Tu et al. [27] showed thatNDRG1directly interactswithb-
catenin and E-cadherin and identiﬁed numerous NDRG1-binding
proteins. Like NDRG1, NDRG2 [26] and PRA1 [15] are also known
to interact with b-catenin, indicating that NDRG2 and PRA1 may
be involved inmodulation of b-catenin nuclear translocation.While
wedidnot observe coimmunoprecipitation of PRA1 and b-catenin in
NDRG2-overexpressing cells, it may be that this interaction is rela-
tively weak or depends on cellular circumstances.
In summary, we demonstrate that NDRG2 and PRA1 synergisti-
cally contribute to inhibition of TCF/b-catenin signaling by block-ing phosphorylation of GSK3b, although the exact mechanism is
not known. Thus, further studies are required to gain insight into
the direct action of NDRG2 or the NDRG2-PRA1 complex in mem-
brane organelle-mediated signal transduction, its control of TCF/b-
catenin signaling, and mechanism(s) involved in colorectal
tumorigenesis.
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